Los Angeles, CANCT05765175Now EnrollingIRB Ready

Tachycardia, Ventricular Clinical Trial in Los Angeles, CA

Access cutting-edge tachycardia, ventricular treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Varian, a Siemens Healthineers Company

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access tachycardia, ventricular specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related tachycardia, ventricular treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this tachycardia, ventricular clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Tachycardia, Ventricular Study in Los Angeles

RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.

Sponsor: Varian, a Siemens Healthineers Company

Who Can Participate

Inclusion Criteria

High-risk refractory VT, defined as:
Ischemic and/or nonischemic cardiomyopathy, and
Recurrent sustained monomorphic VT, defined as at least one of the following below, documented by ICD interrogation or ECG in the prior 6 months, and having occurred after the last VT ablation: A: ≥3 episodes of monomorphic VT treated with anti-tachycardia pacing (ATP) at least one of which is symptomatic B: ≥1 appropriate ICD shock C: ≥3 episodes of sustained monomorphic VT within 24 hours treated with ICD shock or ATP D: sustained monomorphic VT below detection rate of ICD documented by ECG, and
Left ventricular ejection fraction (LVEF) ≤49% and
Previously underwent at least one standard of care CA for VT.
Presence of a clinical indication for a repeat CA procedure for scar-mediated VT in the judgement of the treating investigator.
Has failed amiodarone therapy or is intolerant to amiodarone:
Failed amiodarone therapy is defined as: appropriate ICD therapy or sustained monomorphic VT having occurred while the patient was taking amiodarone (minimum cumulative dose of 10 g).
Intolerant to amiodarone is defined as: previously tried or taken amiodarone but stopped due to medication related side effects or toxicities.
Deemed to be medically and technically a candidate for further CA by the electrophysiologist investigator.
Presence of an ICD.
At least 18 years of age (or meets local age of majority).
Ability to understand and willingness to sign an IRB approved written informed consent document.

Exclusion Criteria

Contraindication to a CA procedure for VT (e.g., presence of mobile LV thrombus, active systemic infection, active ischemic or other reversible causes of VT).
Patients with expected, right ventricular scar only.
Any prior radiation to the thorax region of the body.
Known medical conditions associated with higher risk of radiotherapy complications in the judgement of the radiation oncologist (i.e., active connective tissue disorders, interstitial lung disease, etc.) that would preclude safe delivery of CRA.
Current use of inotropes.
Presence of a left-ventricular assist device (LVAD).
Scheduled for LVAD or heart transplant procedures.
Presence of a systemic illness likely to limit survival to \< 1 year.
VT ablation procedure performed within the prior 2 weeks.
Polymorphic VT or ventricular fibrillation (VF) as the primary clinical heart rhythm, as indicated by 12-lead ECG and/or ICD interrogation.
\>3 distinct clinical monomorphic VT morphologies on ICD interrogation since the prior CA, or \>5 induced monomorphic VT morphologies during NIPS testing.
Incessant VT that is hemodynamically unstable.
Bundle branch reentry (BBR) VT.
Pregnant and/or breastfeeding. (Patient denial is sufficient for enrollment).
Patients of childbearing potential who:
are not on a medically effective means of birth control at the time of screening or do not start a medically effective means of birth control prior to randomization; or
do not agree to continue medically effective means of birth control until they have completed their assigned therapy; or
do not agree to be on a medically effective means of birth control if they are treated with CRA after their index CA procedure.
Patients enrolled in another clinical study the investigator believes to be in conflict with this clinical investigation.
Patients enrolled or planned to be enrolled in another cardiac radioablation clinical study or registry.
Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT05765175) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Tachycardia, Ventricular Treatment Options in Los Angeles, CA

If you're searching for tachycardia, ventricular treatment options in Los Angeles, CA, this clinical trial (NCT05765175) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced tachycardia, ventricular specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all tachycardia, ventricular clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Los Angeles, CA

See all interstitial cystitis clinical trials recruiting in Los Angeles — not just this study.

Browse Interstitial Cystitis Trials in Los Angeles →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA